Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: The first case report for combination efficacy and safety

A case report of a patient with heavily pretreated metastatic breast cancer with ESR1 and PIK3CA mutations demonstrated a promising response with minor toxicity following an all-oral combination of elacestrant plus alpelisib. The researchers concluded that these findings highlight the importance of personalized patient care that uses up-to-date agents and reactive decision-making.